← Back
Oncology

Glecirasib (JAB-21822)

Jacobio Pharma

KRAS G12C inhibitor with promising Phase 2 data. Competing vs sotorasib and adagrasib.

NSCLCKRAS G12C

Linked Studies

NCT05005234PrimaryCOMPLETEDPHASE1, PHASE2

A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

KRAS G12CUpdated Nov 2025
Loading comments…

Also Known As

Development codes

JAB-21822

Other names

glecirasib
Search all trials →Request coverage update